- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00571753
Isoniazid Dose Adjustment According to NAT2 Genotype (IDANAT2)
A Double-blind, Multicentre, Parallel Group, Randomised, Controlled Trial to Evaluate the Possible Benefit of Isoniazid Dose Adjustment According to the Genotype for NAT2 (Arylamine N-acetyltransferase Type 2) in Patients With Pulmonary Tuberculosis
The study is conducted to compare safety and efficacy of isoniazid administered as an adjusted dose based on NAT2 (arylamine N-acetyltransferase type 2)genotype and as a standard dose.
The hypothesis is that the genotype-adjusted dose is superior to the standard dose with regard to hepatotoxicity and early treatment failure, respectively, in the group of slow and rapid acetylators of NAT2.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Sofia, Bulgaria, 1431
- Specialized Hospital for Active Treatment of Pulmonary Diseases "Sveta Sofia"
-
-
-
-
-
Bad Berka, Germany, 99437
- Zentralkrankenhaus Bad Berka GmbH
-
Bad Lippspringe, Germany, 33175
- Karl-Hansen-Klinik
-
Berlin, Germany, 14165
- Helios Klinikum Emil von Behring GmbH
-
Frankfurt am Main, Germany, 60590
- Medizinische Klinik I, Abteilung Pneumologie/Allergologie, Universitätsklinikum Frankfurt am Main
-
Heidelberg, Germany, 69126
- Abteilung Innere Medizin/ Pneumologie, Thoraxklinik am Universitätsklinikum Heidelberg
-
Immenhausen, Germany, 34376
- Lungenfachklinik Immenhausen
-
Köln, Germany, 50931
- Department I of Internal Medicine, University Hospital, University of Cologne
-
Rotenburg, Germany, 27356
- Diakoniekrankenhaus Rotenburg
-
Ulm, Germany, 89081
- Division of Infectious Diseases and Clinical Immunology, Department of Internal Medicine
-
-
-
-
-
Chodzież, Poland, 64-800
- Specialized Hospital of Lung Diseases and Tuberculosis in Wielkopolska in Chodzież
-
Poznan, Poland, 60-569
- Department of Pulmonal Diseases, K. Marcinkowski University of Medical Sciences
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient is informed and given ample time and opportunity to think about her/his participation and has given her/his written informed consent
- Patient is willing and able to comply with all trial requirements, inclusive genotyping procedure
- Patient is between 18 and 75 years of age (inclusive) during the whole trial, male or female
- Patient has newly diagnosed pulmonary tuberculosis for whom daily antituberculosis therapy is indicated
- Patient has a smear-positive sputum
- Patient has radiological evidence of a pulmonary infiltrate.
Exclusion Criteria:
- Patients with known contraindications for isoniazid: acute hepatitis, macroscopic hematuria, allergy to isoniazid, peripheral neuritis, coagulopathy, severe haemorrhagic diathesis, seizure disorders, psychosis
- Patients with advanced or unstable chronic liver disease which is confirmed on results of biochemical or serological tests by eligibility assessment (relevant abnormalities of the following liver tests: ALT, AST, AP, total and conjugated bilirubin; positive serology for hepatitis), if the assessed risk-benefit ratio for the participation in the study is unfavourable (inclusion upon a decision of clinical investigator)
- Patients with a severe, life-threatening disease with a life expectancy of less than 2 years
- Patients known to have AIDS (CD4+ count <200/ml) or HIV-seropositive patients who are receiving HAART (highly active antiretroviral therapy). Note: HIV-positive patients may be included
- Patients with diabetes mellitus
- Patients with renal insufficiency (creatinine clearance < 30mL / min / 1.73m2) and patients on hemodialysis
- Patients with any other clinical conditions suggesting that he/she should not be included (decision of the clinical investigator)
- Patients with chronic infections requiring concomitant systemic antibacterial agents that are also active against M. tuberculosis (i.e. fluoroquinolones, aminoglycosides, macrolides)
- Patients with intake of systemic antibacterial agents that are also active against M. tuberculosis (i.e. fluoroquinolones, aminoglycosides, macrolides) within 4 weeks prior to antituberculosis treatment
- Patients who have ever received antituberculosis chemotherapy
- Patients who take any hepatotoxic agent on regular basis or have taken it within 3 month before study onset
- Patients with known drug / continuous severe alcohol abuse (drinking more than 60 g alcohol daily)
- Patients who participate in other interventional clinical studies;
- Female patients who are pregnant or lactating;
- Female patients not willing and capable to use two different contraceptive methods throughout the study, e.g. double barrier methods (e.g. diaphragm and condom by the partner, intrauterine devise and condom, sponge and condom, spermicide and condom). Acceptable alternatives of effective contraception are also sexual abstinence or vasectomized partner. In contrast, oral contraceptives are not recommended, since the effectiveness of them may be reduced due to a possible interaction with rifampicin
- Patients who are placed in a closed institution as a result of a court or any other authorities' decision
- Patients who are known or suspected not to comply with the study directives and/or known or suspected not to be reliable or trustworthy
- Patients who are known or suspected not to be capable of understanding and evaluating the information that is given to them as part of the formal information policy (informed consent), in particular regarding the foreseeable risks to which they will be exposed.
Patients with any of followings will not be included into evaluation for efficacy:
- Infection with Mycobacterium avium complex
- Resistance of M. tuberculosis to isoniazid at the first screening test (initial culture).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Test
Isoniazid dose adapted according to NAT2 status i.e. appr.
2.5 mg/kg, 5 mg/kg and 7.5 mg/kg for slow, intermediate and rapid acetylators, respectively
|
modified daily isoniazid dose according to NAT2 genotype (appr.
2.5 mg/kg, 5 mg/kg and 7.5 mg/kg for slow, intermediate and rapid acetylators, respectively).
Treatment with a standard isoniazid dose of isoniazid (appr.
5 mg/kg b.w.)
|
Active Comparator: Control
Treatment with standard isoniazid dose (appr.
5 mg/kg b.w.)
|
modified daily isoniazid dose according to NAT2 genotype (appr.
2.5 mg/kg, 5 mg/kg and 7.5 mg/kg for slow, intermediate and rapid acetylators, respectively).
Treatment with a standard isoniazid dose of isoniazid (appr.
5 mg/kg b.w.)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of early treatment failure, defined as continuous or recurrently positive sputum cultures
Time Frame: occurring up to week 8 of therapy
|
occurring up to week 8 of therapy
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Further adverse events of isoniazid
Time Frame: up to week 8 of therapy
|
up to week 8 of therapy
|
Time course of sputum conversion
Time Frame: up to week 8 of therapy
|
up to week 8 of therapy
|
Duration of hospitalization
Time Frame: up to week 8 of therapy
|
up to week 8 of therapy
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Gerd Fätkenheuer, Prof. Dr. med., Department I of Internal MedicineUniversity Hospital, University of Cologne
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Lung Diseases
- Bacterial Infections
- Bacterial Infections and Mycoses
- Gram-Positive Bacterial Infections
- Actinomycetales Infections
- Mycobacterium Infections
- Tuberculosis
- Tuberculosis, Pulmonary
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antimetabolites
- Hypolipidemic Agents
- Lipid Regulating Agents
- Anti-Bacterial Agents
- Antitubercular Agents
- Fatty Acid Synthesis Inhibitors
- Isoniazid
Other Study ID Numbers
- IDANAT2
- EUDRACT Number:2007-000224-41
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Tuberculosis
-
Foundation for Innovative New Diagnostics, SwitzerlandInstitute of Tropical Medicine, Belgium; Research Center Borstel; National Institute...CompletedMultidrug-Resistant Tuberculosis | Isoniazid Resistant Pulmonary Tuberculosis | Rifampicin Resistant Tuberculosis | Pulmonary Tuberculoses
-
Universiteit AntwerpenAurum Institute; University of Stellenbosch; University of the Free State; Free...RecruitingDrug-resistant Tuberculosis | Rifampicin Resistant Tuberculosis | Pulmonary Tuberculoses | Multidrug Resistant TuberculosisSouth Africa
-
Tjip van der WerfGadjah Mada University; The Enose Company, Zutphen the NetherlandsCompletedPulmonary Tuberculosis Suspected | Other Specified Chronic Obstructive Pulmonary Disease | Pulmonary Tuberculosis TB (+) Histology, (-) BacteriologyIndonesia
-
Research Institute of Epidemiology, Microbiology...Active, not recruitingAspergillosis | Pulmonary Tuberculoses | Old Tuberculosis | Active Tuberculosis | Chronic Pulmonary AspergillosisUzbekistan
-
Medecins Sans Frontieres, NetherlandsLondon School of Hygiene and Tropical Medicine; University of Liverpool; Ministry... and other collaboratorsCompletedMulti-drug Resistant Tuberculosis | Pulmonary Tuberculoses | Extensively Drug-Resistant TuberculosisBelarus, South Africa, Uzbekistan
-
Assistance Publique - Hôpitaux de ParisUnknownPulmonary Tuberculosis | Extra Pulmonary TuberculosisFrance
-
Hospital de Clinicas de Porto AlegreFederal University of Rio Grande do SulCompletedPulmonary Tuberculosis | Extra Pulmonary TuberculosisBrazil
-
Radboud University Medical CenterEuropean and Developing Countries Clinical Trials Partnership (EDCTP); Department... and other collaboratorsCompletedPulmonary Tuberculosis (TB)South Africa
-
National Institute of Allergy and Infectious Diseases...International Tuberculosis Research CenterWithdrawnRefractory Pulmonary TuberculosisKorea, Republic of
-
Assiut UniversityUnknownExtra Pulmonary Tuberculosis
Clinical Trials on isoniazid
-
Instituto Nacional de Salud Publica, MexicoWithdrawnDiabetes Mellitus | Latent Tuberculosis
-
Stanford UniversityNational Institute of Allergy and Infectious Diseases (NIAID); Federal University... and other collaboratorsRecruitingTuberculosis Infection | Isoniazid Adverse ReactionBrazil
-
National Institute of Allergy and Infectious Diseases...CompletedHIV Infections | TuberculosisHaiti, South Africa, Thailand, Tanzania, Botswana, Zimbabwe, India, Uganda
-
Hospital Universitari de BellvitgeCellestisCompletedLatent Tuberculosis InfectionSpain
-
National Taiwan University HospitalUnknownLatent Tuberculosis InfectionTaiwan
-
National Institute on Drug Abuse (NIDA)Johns Hopkins UniversityUnknown
-
University of Cape TownLondon School of Hygiene and Tropical Medicine; Johns Hopkins University; Imperial... and other collaboratorsCompletedHIV Infections | Tuberculosis | Latent Tuberculosis InfectionSouth Africa
-
Asan Medical CenterCompleted
-
Pharma 2100WithdrawnArterial Leg UlcerDenmark
-
Makerere UniversityRecruiting